| Original language | English |
|---|---|
| Journal | Blood |
| Volume | 138 |
| Issue number | Supplement 1 |
| Pages (from-to) | 71 |
| ISSN | 0006-4971 |
| DOIs | |
| Publication status | Published - Nov 2021 |
| Event | 63rd ASH Annual Meeting. - Georgia World Congress Center and Virtual, Atlanta, United States Duration: 11. Dec 2021 → 14. Dec 2021 |
Conference
| Conference | 63rd ASH Annual Meeting. |
|---|---|
| Location | Georgia World Congress Center and Virtual |
| Country/Territory | United States |
| City | Atlanta |
| Period | 11/12/2021 → 14/12/2021 |
Documents & Links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. / Eichhorst, Barbara; Niemann, Carsten Utoft; Kater, Arnon P. ; Fürstenau, Moritz; Von Tresckow, Julia ; Zhang, Can; Robrecht, Sandra; Gregor, Michael ; Juliusson, Gunnar ; Thornton, Patrick ; Staber, Philipp B. ; Tadmor, Tamar; Lindström, Vesa ; da Cunha-Bang, Caspar; Schneider, Christof ; Poulsen, Christian Bjørn; Thomas Illmer, Thomas; Schöttker, Björn ; Janssens, Ann ; Christiansen, Ilse; Noesslinger, Thomas ; Baumann, Michael ; van der Klift, Marjolein ; Jaeger, Ulrich Jaeer; Frederiksen, Henrik; B.L. Leijs, Maria ; Hoogendoorn, Mels; Lotfi, Kourosh ; Hebart, Holger ; Gaska, Tobias; Koene, Harry R.; Simon, Florian ; De Silva, Nisha; Fink, Anna-Maria ; Fischer, Kirsten ; Clemens-Martin Wendtner; Kreuzer, Karl-Anton ; Ritgen, Matthias ; Brüggemann, Monika Brüggemann; Tausch, Eugen ; Levin, Mark-David; van Oers, Marinus H J; Geisler, Christian Hartmann; Stilgenbauer, Stephan ; Hallek, Michael .
In: Blood, Vol. 138, No. Supplement 1, 11.2021, p. 71.Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
TY - ABST
T1 - A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial
AU - Eichhorst, Barbara
AU - Niemann, Carsten Utoft
AU - Kater, Arnon P.
AU - Fürstenau, Moritz
AU - Von Tresckow, Julia
AU - Zhang, Can
AU - Robrecht, Sandra
AU - Gregor, Michael
AU - Juliusson, Gunnar
AU - Thornton, Patrick
AU - Staber, Philipp B.
AU - Tadmor, Tamar
AU - Lindström, Vesa
AU - da Cunha-Bang, Caspar
AU - Schneider, Christof
AU - Poulsen, Christian Bjørn
AU - Thomas Illmer, Thomas
AU - Schöttker, Björn
AU - Janssens, Ann
AU - Christiansen, Ilse
AU - Noesslinger, Thomas
AU - Baumann, Michael
AU - van der Klift, Marjolein
AU - Jaeger, Ulrich Jaeer
AU - Frederiksen, Henrik
AU - B.L. Leijs, Maria
AU - Hoogendoorn, Mels
AU - Lotfi, Kourosh
AU - Hebart, Holger
AU - Gaska, Tobias
AU - Koene, Harry R.
AU - Simon, Florian
AU - De Silva, Nisha
AU - Fink, Anna-Maria
AU - Fischer, Kirsten
AU - Clemens-Martin Wendtner,
AU - Kreuzer, Karl-Anton
AU - Ritgen, Matthias
AU - Brüggemann, Monika Brüggemann
AU - Tausch, Eugen
AU - Levin, Mark-David
AU - van Oers, Marinus H J
AU - Geisler, Christian Hartmann
AU - Stilgenbauer, Stephan
AU - Hallek, Michael
PY - 2021/11
Y1 - 2021/11
U2 - 10.1182/blood-2021-146161
DO - 10.1182/blood-2021-146161
M3 - Conference abstract in journal
VL - 138
SP - 71
JO - Blood
JF - Blood
SN - 0006-4971
IS - Supplement 1
Y2 - 11 December 2021 through 14 December 2021
ER -